Watch for the definitive proxy statement and shareholder vote date for the Sun Pharma acquisition. Monitor Q2 earnings for confirmation of the headwinds the CEO cited. The filing contains no deal valuation or financial terms—those will appear in the definitive proxy.
Price Chart
Executive Summary
Organon filed a DEFA14A (additional definitive proxy soliciting material) containing a transcript of an internal all-employee town hall. The transcript provides business updates on the pending acquisition by Sun Pharma, Q1 2026 financial performance (revenue on budget, EBITDA slightly ahead), and strategic priorities. No specific financial figures beyond Q1 being 'right on budget' for revenue and 'slightly ahead' on EBITDA are provided. The filing contains no new material financial data, no change of control terms, and no pricing details for the acquisition.
Key Financial Metrics
Key Facts
- CEO confirmed a preliminary proxy statement was filed on June 1, 2026, for the pending acquisition by Sun Pharma; a final proxy is being prepared to enable the shareholder vote.
- Shareholder vote expected in the 'near future' (not days or months away).
- Q1 2026 revenue came in 'right on budget' and EBITDA was 'slightly ahead' of budget.
- Q2 faces headwinds including supply issues and a distribution partner struggling.
- CEO noted the international commercial business started Q1 with a '+$30 million versus budget' performance.
- CEO described Organon's established brands business as 'a $4 billion part of our business'.
- Targeted restructurings remain planned for Q3 and Q4 2026.
- Closing expected 'early next year' subject to shareholder vote and regulatory approval.
Financial Impact
Q1 2026 revenue on budget, EBITDA slightly ahead; Q2 facing headwinds but CEO expressed confidence in delivering. No material financial guidance change.
Risk Factors
- Shareholder vote may not pass or may be delayed.
- Regulatory/antitrust approvals may extend timeline or impose conditions.
- Planned restructurings and retention challenges could affect operational execution through close.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-266707 |
| Document: 0001193125-26-266707-index-headers.html | 0001193125-26-266707 |
| Document: 0001193125-26-266707-index.html | 0001193125-26-266707 |
| Document: 0001193125-26-266707.txt | 0001193125-26-266707 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | Institutional Cluster | $13.68 | awaiting T+60 | — | $13.74 (−0.44%) |
Jul 31, 2026 12w ago | 8-K | $13.55 $13.74 | ▼ −1.40% | ▲ +1.05% | $13.74 (−1.40%) |
Jul 17, 2026 14w ago | 8-K | $13.49 $13.77 | ▲ +2.08% | ▼ −2.76% | $13.74 (+1.85%) |
Jun 17, 2026 18w ago | DEFM14A | $13.42 $13.64 | ▲ +1.64% | ▼ −1.51% | $13.74 (+2.38%) |
Jun 11, 2026 19w ago | DEFA14A | $13.45 $13.78 | ▲ +2.45% | ▼ −1.94% | $13.74 (+2.16%) |
Jun 1, 2026 21w ago | PREM14A | $13.37 $13.75 | ▲ +2.84% | ▲ +1.87% | $13.74 (+2.81%) |
Apr 30, 2026 25w ago | DEFA14A | $13.25 $13.52 | ▲ +2.08% | ▼ −0.74% | $13.74 (+3.74%) |
Apr 30, 2026 25w ago | 8-K | $13.25 $13.52 | ▼ −2.08% | ▲ +0.74% | $13.74 (−3.74%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers